November 19, 2013Open Access

First FDA Authorization for Next-Generation Sequencer

Key Points

Key points are not available for this paper at this time.

Abstract

The FDA has granted marketing authorization for a high-throughput genomic sequencer, Illumina's MiSeqDx, which will allow the development of innumerable new genome-based tests. Access to genomic data may transform research, clinical care, and patient engagement.

First FDA Authorization for Next-Generation Sequencer

Key Points

Abstract

Cite This Study

Also Consider

Also Consider